Histone deacetylase inhibitors promote the tumoricidal effect of HAMLET

被引:22
作者
Brest, Patrick
Gustafsson, Mattias
Mossberg, Ann-Kristin
Gustafsson, Lotta
Duringer, Caroline
Hamiche, Ali
Svanborg, Catharina
机构
[1] Lund Univ, Inst Lab Med, Sect Microbiol Immunol & Glycobiol, SE-22362 Lund, Sweden
[2] AstraZeneca R&D, Lund, Sweden
[3] Inst Andre Lwoff, CNRS, UPR 9079, Villejuif, France
关键词
D O I
10.1158/0008-5472.CAN-07-1153
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Histone deacetylase inhibitors (HDIs) and HAMLET (human alpha-lactalbumin made lethal to tumor cells) interact with histones, modify the structure of chromatin, and trigger tumor cell death. This study investigated how the combination of HDIs and HAMLET influences cell viability, histone acetylation, and DNA integrity. The pretreatment of tumor cells with HDIs was shown to enhance the lethal effect of HAMLET and the histone hyperacetylation response to HDIs increased even further after HAMLET treatment. HDIs and HAMLET were shown to target different histone domains as HAMLET bound tailless core histones, whereas HDIs modify the acetylation of the histone tail. DNA damage in response to HAMLET was increased by HDIs. The DNA repair response (p21WAFI expression) was induced by both agonists but abolished when the two agonists were combined. The results suggest that the synergy of HDIs and HAMLET is based on different but converging death pathways, both involving chromatin alterations. We speculate that HAMLET and HDIs might be combined to promote tumor cell death in vivo.
引用
收藏
页码:11327 / 11334
页数:8
相关论文
共 41 条
[1]   Apoptosis inhibitory activity of cytoplasmic p21Cip1/WAF1 in monocytic differentiation [J].
Asada, M ;
Yamada, T ;
Ichijo, H ;
Delia, D ;
Miyazono, K ;
Fukumuro, K ;
Mizutani, S .
EMBO JOURNAL, 1999, 18 (05) :1223-1234
[2]   Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of Her-2 [J].
Bali, P ;
Pranpat, M ;
Swaby, R ;
Fiskus, W ;
Yamaguchi, H ;
Balasis, M ;
Rocha, K ;
Wang, HG ;
Richon, V ;
Bhalla, K .
CLINICAL CANCER RESEARCH, 2005, 11 (17) :6382-6389
[3]  
Blagosklonny MV, 2002, MOL CANCER THER, V1, P937
[4]   Anticancer activities of histone deacetylase inhibitors [J].
Bolden, Jessica E. ;
Peart, Melissa J. ;
Johnstone, Ricky W. .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (09) :769-784
[5]   The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL [J].
Butler, Lisa M. ;
Liapis, Vasilios ;
Bouralexis, Stelios ;
Welldon, Katie ;
Hay, Shelley ;
Thai, Le M. ;
Labrinidis, Agatha ;
Tilley, Wayne D. ;
Findlay, David M. ;
Evdokiou, Andreas .
INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (04) :944-954
[6]   Clinical development of histone deacetylase inhibitors as anticancer agents [J].
Drummond, DC ;
Noble, CO ;
Kirpotin, DB ;
Guo, ZX ;
Scott, GK ;
Benz, CC .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2005, 45 :495-528
[7]   HAMLET interacts with histones and chromatin in tumor cell nuclei [J].
Düringer, C ;
Hamiche, A ;
Gustafsson, L ;
Kimura, H ;
Svanborg, C .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (43) :42131-42135
[8]   Human α-lactalbumin made lethal to tumor cells (HAMLET) kills human glioblastoma cells in brain xenografts by an apoptosis-like mechanism and prolongs survival [J].
Fischer, W ;
Gustafsson, L ;
Mossberg, AK ;
Gronli, J ;
Mork, S ;
Bjerkvig, R ;
Svanborg, C .
CANCER RESEARCH, 2004, 64 (06) :2105-2112
[9]  
Fotedar R, 2004, CELL CYCLE, V3, P134
[10]   The conflicting roles of the cdk inhibitor p21(CIP1/WAF1) in apoptosis [J].
Gartel, AL .
LEUKEMIA RESEARCH, 2005, 29 (11) :1237-1238